Anixa Biosciences, Inc. (ANIX): Price and Financial Metrics


Anixa Biosciences, Inc. (ANIX): $4.89

-0.08 (-1.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ANIX Stock Price Chart Interactive Chart >

Price chart for ANIX

ANIX Price/Volume Stats

Current price $4.89 52-week high $6.25
Prev. close $4.97 52-week low $2.30
Day low $4.80 Volume 22,400
Day high $5.03 Avg. volume 81,991
50-day MA $5.03 Dividend yield N/A
200-day MA $3.80 Market Cap 149.94M

Anixa Biosciences, Inc. (ANIX) Company Bio


Anixa Biosciences, Inc., a biotechnology company, develops diagnostics and therapeutics to diagnose, treat, and prevent cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of cancer, which is based on the body's immune response to the presence of a malignancy. It is also developing a vaccine against triple negative breast cancer; and chimeric endocrine receptor T-cell technology focused on treating ovarian cancer. Anixa Biosciences, Inc. has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy technology; and with OntoChem GmbH to develop novel Covid-19 therapeutics. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.


ANIX Latest News Stream


Event/Time News Detail
Loading, please wait...

ANIX Latest Social Stream


Loading social stream, please wait...

View Full ANIX Social Stream

Latest ANIX News From Around the Web

Below are the latest news stories about ANIXA BIOSCIENCES INC that investors may wish to consider to help them evaluate ANIX as an investment opportunity.

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio Breast Cancer Symposium

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining the design of its ongoing breast cancer vaccine trial on December 7, 2022, at the 2022 San Antonio Breast Cancer Symposium.

Yahoo | November 8, 2022

Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer Institute, will Discuss Anixa Biosciences' Ovarian Cancer CAR-T Therapy

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Garcia, Senior Member of the Immunology Department at Moffitt Cancer Center, has been invited to be the keynote speaker at Duke Cancer Institute's Immuno-Oncology Research Program Retreat on November 4, 2022.

Yahoo | October 31, 2022

Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast Cancer Vaccine at Cleveland Clinic

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1b trial for its preventative breast cancer vaccine. The study is being conducted at Cleveland Clinic and will evaluate safety and monitor immune response.

Yahoo | October 26, 2022

Anixa Biosciences (NASDAQ:ANIX) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | October 25, 2022

Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining its ovarian cancer CAR-T therapy trial at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting being held November 8-12, 2022. The presentation, titled "Phase I clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) i

Yahoo | October 10, 2022

Read More 'ANIX' Stories Here

ANIX Price Returns

1-mo -12.05%
3-mo 15.88%
6-mo 19.85%
1-year 58.25%
3-year 29.37%
5-year 102.07%
YTD 64.65%
2021 -3.26%
2020 -6.40%
2019 -16.75%
2018 66.95%
2017 -56.30%

Continue Researching ANIX

Here are a few links from around the web to help you further your research on Anixa Biosciences Inc's stock as an investment opportunity:

Anixa Biosciences Inc (ANIX) Stock Price | Nasdaq
Anixa Biosciences Inc (ANIX) Stock Quote, History and News - Yahoo Finance
Anixa Biosciences Inc (ANIX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7808 seconds.